Skip to content

Study to assess the role of platelet rich fibrin in chronic pain management of musculoskeletal injuries.

A comparative study to evaluate the clinical efficacy of autologous platelets rich fibrin on chronic pain management of musculoskeletal injuries. - NIL

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/12/078382
Enrollment
40
Registered
2024-12-20
Start date
Unknown
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Platelet rich fibrin: Platelet rich fibrin is a second generation platelet Concentrate which Contains platelets,leukocytes,fibronectin,vitronectin and thrombospondin-1.Platelet rich fib

Sponsors

Nil
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients of age group equal or more than 18 years of either sex with ASA grade 1 and 2. 2.Patient suffering from chronic pain due to musculoskeletal injuries for atleast 3 months . 3.Patient having VAS score more than 5 without satisfactory pain relief from standard treatment. 4.Patient who have not received any local injectables like corticosteroids presenting to the pain clinic OPD.

Exclusion criteria

Exclusion criteria: 1. History of previous local anaesthetic infiltration. 2. Malignancy. 3. Active local infection/skin infection 4. Patients on anticoagulant, antiplatelet drugs, bleeding disorders 5. Patient on immunosuppressants/steroids 6. Fever 7. Diabetic mellitus 8. Unwillingness to participate 9. Patients on treatment for psychiatric illness 10. Pregnant and lactating women will be excluded from the study.

Design outcomes

Primary

MeasureTime frame
To assess clinical recovery by VAS score in assessment of local pain before and after PRF injection.Timepoint: To assess clinical recovery by VAS score in assessment of local pain at intervals of baseline,2 weeks, 4 weeks, 8 weeks and 3 months.

Secondary

MeasureTime frame
Requirement of rescue analgesia (Tramadol)Timepoint: 3 months

Countries

India

Contacts

Public ContactDr Monika

Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Science.

monikapunia810@gmail.com8930895596

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026